BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22615811)

  • 1. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
    Jiang Y; Cui L; Chen WD; Shen SH; Ding LD
    PLoS One; 2012; 7(5):e36780. PubMed ID: 22615811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
    Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
    Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
    Sheng X; Guo Y; Lu Y
    Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
    Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
    Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
    Wen G; Wang H; Zhong Z
    Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
    Hu H; Zhou Y; Zhang M; Ding R
    Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.
    Shi DT; Han M; Gao N; Tian W; Chen W
    Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
    Yang J; Niu H; Huang Y; Yang K
    PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
    Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
    PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
    Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
    PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
    Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
    Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
    Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
    Huang YZ; Wu W; Wu K; Xu XN; Tang WR
    Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer.
    Gupta V; Agarwal P; Deshpande P
    Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
    Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
    Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
    Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
    Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
    Niu H; Yang J; Yang K; Huang Y
    Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.